Jinxin Fertility Group Ltd
HKEX:1951

Watchlist Manager
Jinxin Fertility Group Ltd Logo
Jinxin Fertility Group Ltd
HKEX:1951
Watchlist
Price: 2.8 HKD -2.1% Market Closed
Market Cap: 7.7B HKD
Have any thoughts about
Jinxin Fertility Group Ltd?
Write Note

Jinxin Fertility Group Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jinxin Fertility Group Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Jinxin Fertility Group Ltd
HKEX:1951
Long-Term Debt
ÂĄ1.8B
CAGR 3-Years
72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Long-Term Debt
ÂĄ543.7m
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Topchoice Medical Co Inc
SSE:600763
Long-Term Debt
ÂĄ1.2B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Nanjing Xinjiekou Department Store Co Ltd
SSE:600682
Long-Term Debt
ÂĄ500m
CAGR 3-Years
-3%
CAGR 5-Years
37%
CAGR 10-Years
-6%
Dian Diagnostics Group Co Ltd
SZSE:300244
Long-Term Debt
ÂĄ2.1B
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Meinian Onehealth Healthcare Holdings Co Ltd
SZSE:002044
Long-Term Debt
ÂĄ2.7B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
62%
No Stocks Found

Jinxin Fertility Group Ltd
Glance View

Market Cap
7.7B HKD
Industry
Health Care

Jinxin Fertility Group Ltd., a prominent player in the assisted reproduction market, has woven its narrative into the tapestry of modern healthcare by addressing a universal yet profoundly personal concern—fertility. Headquartered in China, this company has emerged at the forefront of fertility services, providing a comprehensive suite of offerings that include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET), among other reproductive technologies. Operating in a market driven by societal shifts such as later-life family planning and increased urbanization, Jinxin Fertility has positioned itself strategically to capitalize on the growing demand for fertility treatments. Through its vast network of clinics across China and in key locations overseas, the company draws a diverse clientele seeking advanced reproductive assistance. What distinguishes Jinxin Fertility Group in this competitive landscape is its blend of cutting-edge technology and high-quality medical expertise. The company invests heavily in research and development to enhance its medical processes, ensuring high success rates and customer satisfaction. This approach not only solidifies its reputation as a trusted provider of fertility solutions but also translates into substantial profitability as clients are willing to invest in reliable and effective treatments for the chance at parenthood. Revenue streams flow from several channels, with core earnings derived from treatment and consultation fees, while ancillary services like genetic testing and cryopreservation contribute additional income. This multifaceted business model not only reinforces Jinxin Fertility’s financial robustness but also underscores its commitment to supporting hopeful parents through every step of their fertility journey.

Intrinsic Value
4.7 HKD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Jinxin Fertility Group Ltd's Long-Term Debt?
Long-Term Debt
1.8B CNY

Based on the financial report for Dec 31, 2023, Jinxin Fertility Group Ltd's Long-Term Debt amounts to 1.8B CNY.

What is Jinxin Fertility Group Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
72%

Over the last year, the Long-Term Debt growth was -29%. The average annual Long-Term Debt growth rates for Jinxin Fertility Group Ltd have been 72% over the past three years .

Back to Top